- Home
- RCMT vs CRDF Comparison
RCMT vs CRDF Comparison
Compare RCMT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCMT
- CRDF
- Stock Information
- Founded
- RCMT 1971
- CRDF 1999
- Country
- RCMT United States
- CRDF United States
- Employees
- RCMT N/A
- CRDF N/A
- Industry
- RCMT Professional Services
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RCMT Consumer Discretionary
- CRDF Health Care
- Exchange
- RCMT Nasdaq
- CRDF Nasdaq
- Market Cap
- RCMT 172.2M
- CRDF 144.4M
- IPO Year
- RCMT N/A
- CRDF N/A
- Fundamental
- Price
- RCMT $26.80
- CRDF $2.01
- Analyst Decision
- RCMT Strong Buy
- CRDF Strong Buy
- Analyst Count
- RCMT 2
- CRDF 5
- Target Price
- RCMT $33.50
- CRDF $11.10
- AVG Volume (30 Days)
- RCMT 45.8K
- CRDF 1.0M
- Earning Date
- RCMT 11-06-2025
- CRDF 11-06-2025
- Dividend Yield
- RCMT N/A
- CRDF N/A
- EPS Growth
- RCMT N/A
- CRDF N/A
- EPS
- RCMT 1.76
- CRDF N/A
- Revenue
- RCMT $299,916,000.00
- CRDF $545,000.00
- Revenue This Year
- RCMT $15.03
- CRDF N/A
- Revenue Next Year
- RCMT $7.49
- CRDF N/A
- P/E Ratio
- RCMT $15.33
- CRDF N/A
- Revenue Growth
- RCMT 11.01
- CRDF N/A
- 52 Week Low
- RCMT $13.18
- CRDF $1.90
- 52 Week High
- RCMT $28.27
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- RCMT 57.09
- CRDF 35.43
- Support Level
- RCMT $26.23
- CRDF $1.97
- Resistance Level
- RCMT $27.55
- CRDF $2.27
- Average True Range (ATR)
- RCMT 0.89
- CRDF 0.12
- MACD
- RCMT -0.08
- CRDF 0.03
- Stochastic Oscillator
- RCMT 51.79
- CRDF 29.73
About RCMT RCM Technologies Inc.
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.